Want to see JP:7096 full AI Analyst Report?

StemCell Institute (7096) Price & Analysis

0 Followers

7096 Stock Chart & Stats

¥793.00

¥110.00(8.02%)

At close: Jan 08 4:00 PM EST

¥793.00

¥110.00(8.02%)

Day’s Range― - ―

52-Week Range¥627.00 - ¥1,085.00

Previous CloseN/A

Volume70.10K

Average Volume (3M)28.64K

Market Cap

¥7.76B

Enterprise Value¥5.61K

Total Cash (Recent Filing)¥2.83B

Total Debt (Recent Filing)¥473.81M

Price to Earnings (P/E)52.7

Beta0.50

Next Earnings

Nov 10, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)15.24

Shares Outstanding10,246,600

10 Day Avg. Volume23,150

30 Day Avg. Volume28,640

Financial Highlights & Ratios

PEG Ratio-0.84

Price to Book (P/B)2.88

Price to Sales (P/S)2.75

P/FCF Ratio-23.04

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)10.9

Revenue Forecast (FY)¥3.10B

Bulls Say, Bears Say

Bulls Say

Steady Revenue GrowthContinued revenue expansion indicates ongoing customer demand and market traction. Although growth has moderated from earlier years, positive top-line performance provides a durable base for rebuilding profitability if execution improves.

Solid Gross MarginA gross margin near 61% suggests the underlying offering retains attractive unit economics and may provide pricing or product-mix support. This gives the company a foundation to absorb investment costs and restore operating leverage over time.

Low Current LeverageModest leverage and expanding equity and assets support financial resilience. The relatively low debt burden should preserve flexibility to fund operations and strategic investment, provided cash-flow deterioration does not persist.

Bears Say

Sharp Profitability CompressionThe steep decline in net and operating profitability weakens earnings quality and reduces the conversion of revenue into shareholder returns. Sustained margin pressure could limit internal funding and increase sensitivity to execution or cost-control challenges.

Negative Free Cash FlowA large free-cash-flow deficit reduces near-term self-funding capacity and may reflect heavy investment, working-capital drag, or both. If the deterioration continues, the company could need additional financing despite its currently modest leverage.

Rising Leverage With Lower ReturnsThe newer capital structure has not yet translated into stronger shareholder returns, raising questions about capital-allocation effectiveness. Further borrowing could increase financial risk if profitability and cash generation remain weak.

StemCell Institute News

StemCell Institute Expands into Southeast Asia with Joint Venture

The latest announcement is out from StemCell Institute ( ($JP:7096) ). StemCell Institute Inc. has entered a joint...

1y ago

7096

7096 FAQ

What was StemCell Institute’s price range in the past 12 months?

StemCell Institute lowest stock price was ¥627.00 and its highest was ¥1085.00 in the past 12 months.

What is StemCell Institute’s market cap?

StemCell Institute’s market cap is ¥7.76B.

When is StemCell Institute’s upcoming earnings report date?

StemCell Institute’s upcoming earnings report date is Nov 10, 2026 which is in 84 days.

How were StemCell Institute’s earnings last quarter?

StemCell Institute released its earnings results on Aug 06, 2026. The company reported ¥3.57 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is StemCell Institute overvalued?

According to Wall Street analysts StemCell Institute’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does StemCell Institute pay dividends?

StemCell Institute pays a Notavailable dividend of ¥25 which represents an annual dividend yield of N/A. See more information on StemCell Institute dividends here

What is StemCell Institute’s EPS estimate?

StemCell Institute’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does StemCell Institute have?

StemCell Institute has 10,246,600 shares outstanding.

What happened to StemCell Institute’s price movement after its last earnings report?

StemCell Institute reported an EPS of ¥3.57 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.959%.

Which hedge fund is a major shareholder of StemCell Institute?

Currently, no hedge funds are holding shares in JP:7096

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

StemCell Institute

StemCell Institute Inc. provides specialized stem cell banking services throughout Japan. In addition to its core preservation activities, the company is deeply involved in the research and development of medical therapies that utilize stem cells, and it also offers banking solutions for blood vessel cells. Founded in 1999, StemCell Institute Inc. is headquartered in Tokyo, Japan, and operates as a subsidiary of Trim Medical Holdings Inc.